Apollo Hospitals also remains Citi’s preferred pick in the Indian hospitals space. Its positive stance is predicated on:
- A structurally-resilient hospital business.
- A fast-growing pharmacy business with digital profitability in sight.
- Valuations, which remain below long-term means on an absolute and a relative basis.
Apollo Hospitals reported a strong set of earnings in the December quarter, with its performance beating Street estimates across parameters.
Its net profit increased 35% to ₹502.3 crore from the previous year and revenue from operations rose 17.2% to ₹6,477 crore.The company’s EBITDA stood at ₹965 crore, up 26.7% from the previous year’s 762.
Its operating margin expanded to 14.9% from 13.8% in the year-ago period.
30 analysts have coverage on Apollo Hospitals, of which 27 have a “buy” rating, two say “hold”, and one has a “sell” rating.
Shares of Apollo Hospitals are trading 4.3% higher on Tuesday at ₹7,455. The stock has turned positive on a year-to-date basis after today’s moves, trading with gains of 5%.
Also Read: Motilal Oswal does not see significant upside on Urban Company as multiple risks lie ahead

